CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer

Clinical and Translational Oncology

Volumn 15, Issue 10, 2013, Pages 789-795

  Jiao, W ^a   Zhao, J ^a   Wang, M ^a   Wang, Y ^a   Luo, Y ^a   Zhao, Y ^a   Tang, D ^a   Shen, Y ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

CUGBP1; CUGBP1mRNA; Non small cell lung cancer; Prognosis

Indexed keywords

CUG BINDING PROTEIN 1; MESSENGER RNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SURVIVAL PREDICTION; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885175429     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1005-5     Document Type: Article

References (27)

1. Kang S, Koh ES, Vinod SK, Jalaludin B (2012) Cost analysis of lung cancer management in South Western Sydney. J Med Imaging Radiat Oncol 56(2):235-241
2. Ciervide R, Dhage S, Guth A, Shapiro RL, Axelrod DM, Roses DF et al (2012) Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys 83(2):e159-e164
3. Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, Inoue M et al (2009) WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer 125(2):381-387
4. Ward AJ, Rimer M, Killian JM, Dowling JJ, Cooper TA (2010) CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet 19(18):3614-3622
5. Koshelev M, Sarma S, Price RE, Wehrens XH, Cooper TA (2010) Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet 19(6):1066-1075
6. Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ et al (2009) Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 106(33):13915-13920
7. Garbarino-Pico E, Green CB (2007) Posttranscriptional regulation of mammalian circadian clock output. Cold Spring Harb Symp Quant Biol 72:145-156
8. Zheng Y, Miskimins WK (2011) CUG-binding protein represses translation of p27Kip1 mRNA through its internal ribosomal entry site. RNA Biol 8(3):365-371
9. Zhang L, Lee JE, Wilusz J, Wilusz CJ (2008) The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. J Biol Chem 283(33):22457-22463
10. Andrews J, Yeh P, Pao W, Horn L (2011) Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J 17(2):104-113
11. Pelosi G, Sonzogni A, Viale G (2010) The classification of lung carcinoma: time to change the morphology-based approach? Int J Surg Pathol 18(3):161-172
12. Cui YH, Xiao L, Rao JN, Zou T, Liu L, Chen Y et al (2012) miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies. Mol Biol Cell 23(1):151-162
13. Arnal-Estape A, Tarragona M, Morales M, Guiu M, Nadal C, Massague J et al (2010) HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms. Cancer Res 70(23):9927-9936
14. Rattenbacher B, Beisang D, Wiesner DL, Jeschke JC, von Hohenberg M, St Louis-Vlasova IA et al (2010) Analysis of CUGBP1 targets identifies GU-repeat sequences that mediate rapid mRNA decay. Mol Cell Biol 30(16):3970-3980
15. Timchenko NA, Patel R, Iakova P, Cai ZJ, Quan L, Timchenko LT (2004) Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem 279(13):13129-13139
16. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC et al (2009) EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 4(3):318-325
17. Thorsteinsson H, Jonsson S, Alfredsson H, Isaksson HJ, Gudbjartsson T (2009) Results of pneumonectomy for non-small cell lung cancer in Iceland. Laeknabladid 95(12):823-829
18. Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A (1995) Survival predictors in advanced non-small cell lung cancer. Lung Cancer 13(3):253-267
19. Koo HK, Jin SM, Lee CH, Lim HJ, Yim JJ, Kim YT et al (2011) Factors associated with recurrence in patients with curatively resected stage I-II lung cancer. Lung Cancer 73(2):222-229
20. Dediu M, Crisan E, Radut M, Tarlea A, Median D, Alexandru A et al (2009) The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study. Lung Cancer 63(2):271-276
21. Dundar E, Oner U, Peker BC, Metintas M, Isiksoy S, Ak G (2008) The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. J Int Med Res 36(1):88-95
22. Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA (2009) PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 119(12):3797-3806
23. Hoody DW, Beckett CF, Zielenski C, Moore GD (2011) Quality of drug information database research for clinical decision support. Int J Clin Pharm 33(4):599-602
24. Othman M, Falcon BJ, Kadir R (2010) Global hemostasis in pregnancy: are we using thromboelastography to its full potential? Semin Thromb Hemost 36(7):738-746
25. Xiao H, Ding J, Gao S, Yang S, Huang Y (2011) Never smokers with lung cancer: analysis of genetic variants. Asian Pac J Cancer Prev 12(10):2807-2809
26. Grutters JP, Pijls-Johannesma M, Ruysscher DD, Peeters A, Reimoser S, Severens JL et al (2010) The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev 36(6):468-476
27. Chhatwani L, Cabebe E, Wakelee HA (2009) Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc 6(2):194-200